Shares of St. Jude Medical fell after the FDA released a plant inspection report that found problems in the company’s testing and oversight of an electrical wire, or lead, that connects an implanted defibrillator to a patient’s heart. The FDA report raises the prospect of potential agency action. St. Jude executives have repeatedly insisted the lead is safe.